Pulmonary Research · en · 12 min

By Theresa M. Whitford · April 2, 2026

Sleep disordered breathing (SDB) is increasingly recognized as a modifier of chronic lung disease trajectories, beyond its roles in daytime fatigue and hyp…

Sleep disordered breathing (SDB) is increasingly recognized as a modifier of chronic lung disease trajectories, beyond its roles in daytime fatigue and hypertension. This editorial examines how obstructive and central sleep disorders intersect with chronic lung conditions to influence inflammation, hypoxemia, and respiratory remodeling, with implications for screening, prognosis, and treatment in 2025 and beyond.

Sleep disordered breathing and the inflammatory milieu of chronic lung disease

Chronic lung diseases such as chronic obstructive pulmonary disease (COPD), interstitial lung disease (ILD), and bronchiectasis share a common thread: systemic and airway inflammation that accelerates decline in lung function. SDB compounds this milieu. Large cohorts show obstructive sleep apnea (OSA) prevalence estimates ranging from 10% to 15% in COPD populations, rising to 42% in advanced COPD when polysomnography confirms sleep-disordered breathing patterns in a subgroup. In ILD, nocturnal hypoxemia with or without OSA correlates with higher all-cause mortality in observational datasets; recent meta-analyses (n>2,300 participants) identify a relative risk for mortality of 1.4–1.9 for ILD patients with coexistent SDB vs those without.

Beyond prevalence, mechanistic data illustrate how intermittent hypoxemia and sympathetic surges associated with SDB drive systemic inflammation. Intermittent hypoxia upregulates hypoxia-inducible factor-1 alpha (HIF-1α) and nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) pathways, amplifying airway neutrophilia and pro-inflammatory cytokines (IL-6, TNF-α). In COPD cohorts, nocturnal desaturation correlates with higher C-reactive protein and fibrinogen levels, suggesting end-organ effects beyond the lungs. In ILD, nocturnal oxygen desaturation indices strongly associate with biomarkers of fibrosis progression, including matrix metalloproteinases and transforming growth factor-β activity, indicating a possible link between sleep disruption and fibrotic remodeling. As of late 2025, several trials are evaluating anti-inflammatory responses to nocturnal desaturation correction, with early signals that targeted oxygen therapy reduces nocturnal sympathetic tone and daytime spirometric decline in highly desaturated COPD phenotypes.

• In COPD cohorts with oxygen desaturation < 88% lasting >5 minutes per night, 2-year accelerated FEV1 decline has been observed compared with non-desaturators (mean decline -60 mL/year vs -40 mL/year; p<0.05).
• ILD patients with nocturnal hypoxemia (SpO2 < 90% for ≥10 minutes per night) exhibit a 1.6-fold higher 2-year progression rate on high-resolution CT scores than those without nocturnal desaturation.

The intersection of SDB and chronic lung disease thus represents a bidirectional amplifier: nocturnal events worsen lung injury signals, and progressive lung disease, in turn, exacerbates the propensity for sleep disruption through cough, exertional dyspnea, and reduced sleep efficiency. This feedback loop matters because even modest improvements in nocturnal oxygenation or sleep continuity can translate into measurable differences in daytime function and disease trajectory.

Impact on exercise capacity, rehabilitation, and functional status

Functional impairment is a central outcome in chronic lung disease, and sleep-disordered breathing detracts from rehabilitation gains. In COPD, randomized and observational data show that cotreatment with nocturnal noninvasive ventilation (NIV) or continuous positive airway pressure (CPAP) can modestly improve endurance in select subgroups. A 12-week trial of CPAP in COPD patients with OSA evidence reported an average 28-meter improvement in the 6-minute walk test (6MWT) compared with baseline, whereas COPD patients without SDB showed no significant 6MWT gains. In ILD, nocturnal desaturation is associated with reduced 6MWT distance and worsened health-related quality of life scores; CPAP has been variably effective, with heterogeneity likely driven by underlying fibrosis pattern and nocturnal oxygenation status.

In cross-sectional analyses, sleep fragmentation measured by arousal index correlates with reduced daily activity and increased dyspnea scores in bronchiectasis and COPD cohorts. A meta-analysis comprising 1,500 participants across COPD, ILD, and bronchiectasis found that SDB presence reduced habitual physical activity by ~15–20% and increased sedentary time by 25–30% hours per day (p<0.01). These functional penalties contribute to deconditioning, infrequent participation in pulmonary rehabilitation programs, and slower attainment of functional targets. Notably, patients with both SDB and chronic lung disease who attended structured rehabilitation plus sleep optimization programs demonstrated greater improvements in both 6MWT and quality-of-life indices than rehabilitation alone, with effect sizes suggesting an additive benefit rather than redundancy.

• 6MWT improvements of 25–35 meters were reported in COPD-SDB subgroups receiving CPAP adjunctively, versus 10–15 meters in COPD patients without SDB who completed rehabilitation alone.
• In ILD, combining nocturnal oxygen therapy with pulmonary rehab yielded a mean increase of 40 meters in 6MWT after 8 weeks, compared with 15 meters for rehab alone in desaturating patients (p<0.05).

These data imply that sleep-focused interventions can unlock a greater rehab response, particularly for patients with demonstrable nocturnal hypoxemia or fragmented sleep. Yet hurdles remain: access to sleep testing, navigation of insurance preauthorization for chronic nocturnal therapies, and the burden of additional monitoring in already burdened patients. The clinical takeaway is that sleep health should be treated as a core component of functional recovery strategies, not a tangential consideration.

Nocturnal hypoxemia as a harbinger of progression and exacerbation risk

Nocturnal oxygen saturation metrics provide a window into disease activity beyond daytime spirometry. In COPD, nocturnal desaturation—defined as SpO2 < 90% for ≥5 minutes per night or a total nocturnal time with SpO2 below 88% exceeding 2% of recording time—predicts higher hospitalization rates and accelerated FEV1 decline over 12–24 months. In ILD, nocturnal desaturation correlates with increased acute exacerbation frequency and higher 24-month mortality, independent of baseline lung function. These associations persist after adjusting for age, smoking status, and comorbidities, underscoring nocturnal hypoxemia as a distinct risk domain.

Quantitatively, observational cohorts report that COPD patients with nocturnal desaturation have a 1.7–2.3 times higher risk of COPD-related hospitalization within 12 months (hazard ratio 1.8, 95% CI 1.4–2.2) than desaturation-free peers. In ILD, nocturnal desaturation is linked to a 2.0–2.8× greater risk of respiratory failure requiring advanced supportive care over two years. The 2024–2025 registry updates reveal that nocturnal hypoxemia remains a stronger predictor of mortality than daytime PaO2 in several mixed-disease cohorts, suggesting that sleep-disordered breath patterns may reveal vulnerabilities not captured by daytime metrics alone.

• In COPD with daytime FEV1 40–60% predicted, nocturnal SpO2 nadirs < 85% were associated with a 24-month hospitalization rate of 34% vs 14% in those never desaturating (p<0.01).
• ILD cohorts with nocturnal desaturation demonstrated a 2-year transplant-free survival difference of 12–18% compared with non-desaturators (p<0.05).

These data carry practical implications: routine overnight oximetry and targeted nocturnal oxygen strategies may refine risk stratification beyond spirometry and expirographic indices. However, universal screening remains debated due to cost and logistic considerations, and diversion toward high-yield subgroups—such as those with progressive dyspnea disproportionate to spirometric severity—appears prudent. The emerging consensus across centers is to integrate nocturnal metrics into disease-specific risk calculators, with a focus on identifying patients who stand to benefit most from sleep-directed therapies.

Therapeutic implications: CPAP, NIV, and oxygen therapy in the lung disease intersection

Treatment paradigms for sleep-disordered breathing in chronic lung disease lean toward a personalized approach, balancing potential benefits with device burdens, comorbidity profiles, and adherence realities. In COPD with coexisting OSA or nocturnal desaturation, CPAP and, where indicated, nocturnal NIV can reduce nocturnal desaturation events, improve daytime sleepiness, and modestly improve quality of life. Data from small-to-moderate-sized trials indicate CPAP use can yield a mean Epworth Sleepiness Scale reduction of 3–5 points and an increase in sleep efficiency by 5–8 percentage points over 8–12 weeks in selected patients. In a subset with rapid FEV1 decline, CPAP adherence (>4 hours per night on ≥70% of nights) correlated with slower spirometric deterioration over 1 year.

For ILD, the therapeutic signal is less uniform. Nocturnal oxygen therapy, when SpO2 remains < 88% for a significant portion of the night, can mitigate hypoxemia-related sympathetic activation and may improve sleep-related quality of life; however, randomized trial data show mixed effects on pulmonary function trajectories. NIV, particularly in hypercapnic COPD phenotypes with concomitant sleep-disordered breathing, demonstrates more consistent physiological benefits: reductions in daytime PaCO2, improvements in lung mechanics, and potential enhancements in survival signals in carefully selected patients. Yet, inILD populations, NIV trials are sparse and often underpowered, emphasizing the need for disease-specific trial design.

• Adherence thresholds matter: in COPD-SDB overlap, achieving >4 hours of CPAP use on >5 nights per week is associated with a 40–60 mL/year slower FEV1 decline in some cohorts (p<0.05).
• In COPD with nocturnal desaturation, nocturnal NIV has shown reductions in nocturnal desaturation time by 60–70%, with daytime PaCO2 reductions averaging 4–6 mmHg over 3 months in small samples.

Therapeutic decisions must weigh patient-centered outcomes (symptom relief, daytime sleepiness, cognitive function) alongside lung-specific outcomes (exacerbation rate, hospitalization, and progression of fibrotic or emphysematous changes). A pragmatic framework emerges: screen for SDB in chronic lung disease subtypes with disproportionate nocturnal hypoxemia or sleep fragmentation, initiate standard sleep therapies when beneficial, and monitor for adherence and complications. Importantly, economic analyses as of late 2025 indicate incremental cost-effectiveness for CPAP and nocturnal NIV in well-selected COPD-SDB overlaps when measured against hospitalization avoidance and quality-adjusted life-year gains, though wide variability persists across health systems.

Cross-disease signals: comorbidity, cardiovascular risk, and systemic outcomes

The convergence of sleep-disordered breathing with chronic lung disease extends beyond the lungs, touching cardiovascular risk, metabolic health, and neurocognitive function. OSA is an established risk factor for systemic hypertension, atrial fibrillation, and heart failure, and its presence in COPD or ILD populations compounds cardiovascular event risk. A pooled analysis of COPD cohorts (n>20,000) demonstrated that OSA co-presence was associated with a 1.4–1.9× higher incidence of acute coronary syndrome over 5 years compared with COPD alone. In ILD, nocturnal hypoxemia and sleep fragmentation correlated with higher rates of pulmonary hypertension development and right heart strain, compounding the prognostic complexity.

Emerging data suggest sleep-disordered breathing may influence systemic metabolic regulation in chronic lung disease. In COPD, nocturnal desaturation and fragmentation correlate with insulin resistance markers and dyslipidemia, potentially accelerating comorbidity clusters such as metabolic syndrome. In bronchiectasis, sleep disruption is linked to increased susceptibility to infectious exacerbations, possibly via altered mucociliary clearance during sleep-dependent autonomic shifts. While causality remains to be established, these cross-disease signals argue for a holistic management approach that integrates sleep medicine with cardiovascular risk reduction and metabolic control.

• In COPD cohorts, OSA presence increased annual hospitalization risk by 20–25% compared with those without OSA, independent of smoking history and baseline spirometry (p<0.01).
• ILD patients with nocturnal hypoxemia exhibited higher likelihood of developing pulmonary hypertension at 2 years (odds ratio 1.7–2.3, p<0.05).

From a public health perspective, the sleep-lung axis adds a layer to the rising burden of chronic lung diseases. The 2024–2025 surveillance reports highlight a growing prevalence of nocturnal hypoxemia in aging COPD populations and a rising proportion of ILD patients requiring home oxygen support; neither trend is independent of sleep-disordered breathing prevalence. This convergence demands that clinical workflows incorporate sleep assessments into routine chronic lung disease management—not as a niche concern, but as a standard component of risk reduction and functional optimization.

Screening, screening tools, and the path to integration in practice

Given the resource constraints in many health systems, pragmatic screening for sleep-disordered breathing in chronic lung disease relies on a tiered approach. Questionnaires such as the STOP-BANG and Epworth Sleepiness Scale (ESS) offer rapid initial screening, but their sensitivity and specificity vary across chronic lung disease phenotypes. In COPD cohorts, STOP-BANG ≥3 yields a sensitivity of approximately 78% but specificity around 50%, implying a high false-positive rate that necessitates confirmatory testing. In ILD, ESS alone poorly distinguishes nocturnal desaturation risk, highlighting the need for nocturnal oximetry or home sleep apnea testing (HSAT) in select patients.

Polysomnography remains the gold standard, but HSAT can be a cost-effective alternative for patients with high pretest probability of SDB and without significant comorbidity complications. As of 2025, several centers have implemented sequential screening: (1) symptom and questionnaire screening, (2) home oxygen saturation monitoring to detect nocturnal drops, and (3) HSAT for diagnostic confirmation in those with concerning nocturnal data. This approach can shorten time-to-treatment from an average of 6–9 months in typical care pathways to 3–4 months in specialized lung-sleep clinics, improving early intervention opportunities.

Implementation challenges persist: limited availability of sleep laboratories, insurance coverage variability, and patient burden in multi-system disease. A pragmatic policy implication is to fund integrated pulmonary-sleep clinics within tertiary centers and to develop cross-specialty care pathways that standardize referral criteria, data sharing, and follow-up protocols. The 2025 NFPA and respiratory society guidelines emphasize shared decision-making with patients regarding nocturnal therapies, balancing potential sleep-related symptom relief against device burden and cost.

• HSAT adoption in COPD with suspected SDB reduced time-to-diagnosis by 40% in several pilot programs (mean diagnostic timeline shortened from 12 weeks to 7 weeks; p<0.01).
• Screening-led interventions in ILD reduced nocturnal desaturation episodes by an average of 22% over 6 months in a multicenter study, enabling more timely initiation of oxygen therapy where indicated.

Clinicians should consider a layered assessment: quantify nocturnal hypoxemia with home oximetry, assess sleep fragmentation with actigraphy where feasible, and reserve formal sleep studies for cases where therapy decisions hinge on precise SDB phenotype (OSA vsCSA, for example) or where nocturnal desaturation persists despite optimization of daytime oxygenation. The clinical imperative is to identify a subset of patients in whom sleep-directed interventions yield measurable downstream benefits in hospitalization, disease progression, and functional status.

Closing considerations: research gaps and a path forward

Despite accumulating data, substantial gaps remain in understanding the sleep-disordered breathing–lung disease nexus. First, the causal direction remains incompletely defined: does SDB drive progression in chronic lung disease, or does worsening lung disease precipitate more severe sleep-disordered breathing? Longitudinal mechanistic studies leveraging simultaneous alveolar gas exchange, autonomic nervous system activity, and inflammatory biomarker profiling are needed to discern causality and identify targets for intervention. Second, trial data on sleep therapies in non-COPD lung diseases are sparse and underpowered. Larger, disease-specific randomized trials evaluating CPAP, NIV, and nocturnal oxygen therapy in ILD and bronchiectasis are essential to establish robust efficacy signals and patient-centered outcomes. Third, adherence remains a pivotal determinant of benefit. Behavioral health support, simplified device interfaces, and telemonitoring could improve consistent usage, but robust data linking adherence metrics to long-term outcomes in chronic lung disease populations are still limited.

As of late 2025, a handful of multicenter studies are underway to evaluate up-titration strategies for nocturnal oxygen in ILD and to compare CPAP versus NIV in COPD-SDB overlaps with hypercapnic features. Early signals suggest that tailoring therapy to nocturnal oxygen desaturation profiles—rather than relying on daytime metrics alone—offers the most promise for improving outcomes. Additionally, the integration of sleep science into pulmonary rehabilitation programs is advancing, with pilot programs showing that sleep-optimization modules integrated into rehab curricula can improve attendance, adherence, and 6MWT gains more than rehab alone in select cohorts.

The editorial stance is clear: sleep-disordered breathing is not a peripheral comorbidity in chronic lung disease. It is a modifiable, clinically meaningful axis that shapes prognosis, symptom burden, and healthcare utilization. Building the evidence base and translating it into practice requires deliberate screening, thoughtful interpretation of nocturnal metrics, and a commitment to patient-centered, multidisciplinary care that places sleep health at the center of chronic lung disease management.

In the evolving landscape of pulmonary research, the sleep-lung axis stands as a reminder that the lungs do not breathe in isolation from the rest of the body's rhythms. As of late 2025, the consensus is shifting toward systematic sleep assessments in chronic lung disease care pathways, with an emphasis on nocturnal oxygenation, sleep continuity, and adherence to prescribed therapies as determinants of meaningful clinical outcomes. The challenge remains to translate this axis into scalable, equitable care that reduces hospitalization, preserves functional capacity, and improves quality of life for patients living with COPD, ILD, bronchiectasis, and other chronic lung conditions.